Site and Timing of First Relapse in Stage III Melanoma Patients: Implications for Follow-Up Guidelines
Emanuela Romano(Kettering University), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Daniel G. Coit(Memorial Sloan Kettering Cancer Center), Michael Scordo(Cornell University), Stephen W. Dusza(Memorial Sloan Kettering Cancer Center)
Cited by 253
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k